A5049041037- Colorectal Cancer Treatments and Studies
- Melanoma and MAPK Pathways
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Cancer Research and Treatments
- Cancer therapeutics and mechanisms
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Pharmacogenetics and Drug Metabolism
- Neutropenia and Cancer Infections
- HER2/EGFR in Cancer Research
- Colorectal and Anal Carcinomas
- Migraine and Headache Studies
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- Ovarian cancer diagnosis and treatment
- Neuroscience of respiration and sleep
- Bone health and osteoporosis research
- MicroRNA in disease regulation
- Colorectal Cancer Surgical Treatments
- Pharmacological Receptor Mechanisms and Effects
- Bone Metabolism and Diseases
- Estrogen and related hormone effects
- Fatty Acid Research and Health
Istituto Oncologico Veneto
2006-2021
Istituti di Ricovero e Cura a Carattere Scientifico
2010-2021
University of Padua
2019
Centro di Riferimento Oncologico
2005-2018
Université d'Angers
2016
Inserm
2016
Oncology Institute of Vojvodina
2012
Ospedale San Filippo Neri
2009
University of Chicago
2009
Cancer Research Center
2009
Purpose UGT1A1*28 polymorphism has been associated with decreased glucuronidation of SN38, the active metabolite irinotecan. This could increase toxicity this agent. Patients and Methods In a prospective study, 250 metastatic colorectal cancer patients were treated irinotecan, fluorouracil, leucovorin as first-line treatment. was investigated respect to distribution hematologic nonhematologic toxicity, objective response rate, survival. Pharmacokinetics in subgroup (71 250) who had analyzed...
PURPOSE More than 50% of patients with stage IV colorectal cancer (metastatic [mCRC]) relapse postresection. The efficacy postoperative systemic treatment is limited in this setting. Thus, these would greatly benefit from the use a reliable prognostic biomarker, such as circulating tumor DNA (ctDNA) to identify minimal or molecular residual disease (MRD). PATIENTS AND METHODS We analyzed cohort 112 mCRC who had undergone metastatic resection curative intent part PREDATOR clinical trial....
Purpose UGT1A1 ★ 28 is considered the main pharmacogenetic predictor of toxicity outcome irinotecan-treated patients. We evaluated effect other UGT1A variants and haplotypes involved in 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation on severe efficacy fluorouracil, leucovorin, irinotecan (FOLFIRI). Patients Methods In addition to 28, 60, 93, UGT1A7 3, UGT1A9 22 were genotyped 250 metastatic colorectal cancer patients, associations with hematologic nonhematologic toxicity, objective...
Abstract Background Immunotherapy with immune checkpoint inhibitors (ICIs) is highly effective in microsatellite instability–high (MSI-H) metastatic colorectal cancer (mCRC); however, specific predictive biomarkers are lacking. Patients and Methods Data samples from 85 patients MSI-H mCRC treated ICIs were gathered. Tumor infiltrating lymphocytes (TILs) tumor mutational burden (TMB) analyzed an exploratory cohort of “super” responders “clearly” refractory patients; TILs then evaluated the...
Abstract Purpose: BRAF mutations are grouped in activating RAS-independent signaling as monomers (class 1–V600E) or dimers 2–codons 597/601), and RAS-dependent with impaired kinase activity 3–codons 594/596). Although clinical, pathologic, molecular features of V600EBRAF-mutated metastatic colorectal cancer (mCRC) well known, limited data available from the two other classes. Experimental Design: Data 117 patients (92 class 1, 12 2, 13 3)-mutated mCRC were collected. A total 540 wt mCRCs...
Abstract Purpose: The germ-line polymorphisms TP53 Arg72Pro and MDM2 SNP309 T>G are risk factors for tumor development affect response to chemotherapy survival in several cancers, but their prognostic predictive value patients with high-grade osteosarcomas is not yet defined. purpose of this study was investigate the effect on osteosarcoma survival. Experimental Design: relative develop overall associated were investigated 201 patients. Correlations event-free (EFS) analyzed a...
This study aimed to identify associations between germline polymorphisms and risk of high-grade osteosarcoma (HGOS) development, event-free survival (EFS) toxicity in HGOS patients treated with neo-adjuvant chemotherapy surgery.Germline 31 genes known be relevant for transport or metabolism all four drugs used (methotrexate, doxorubicin, cisplatin ifosfamide) were genotyped 196 470 healthy age gender-matched controls. Of these patients, a homogeneously group 126 was considered analyses...
V600EBRAF mutated metastatic colorectal cancer (mCRC) is a subtype (10%) with overall poor prognosis, but the clinical experience suggests great heterogeneity in survival. It still unexplored real distribution of traditional and innovative biomarkers among mCRC which their role improvement prediction survival outcomes.Data tissue specimens from 155 patients treated at eight Italian Units Oncology were collected. Specimens analysed by means immunohistochemistry profiling performed on...
Omega-3 polyunsaturated fatty acids (OPFA) have beneficial effects on inflammatory reactions and production of cytokines. They decrease the release 5HT by platelets possess vasorelaxant activity. This led them to be tried in prophylactic treatment migraine. After 4 weeks a single-blind placebo run-in period, patients were randomized treated double-blind condition or OPFA 6 g day for 16 weeks, followed 4-week run-out period. The intention treat population included 196 patients. Those who...
Irinotecan (CPT11) is a prodrug activated in humans mainly by carboxylesterase 2 (CES2) generating the SN38 metabolite responsible for drug efficacy and toxicity. The interpatients variability CPT11 activation step could cause unpredictable To identify predictive molecular marker cancer patients, we investigated CES2 mRNA expression peripheral blood mononuclear cells (PBMC) correlated it to rate, toxic effects, response.Forty-five colorectal patients were treated with CPT11-including regimen...
Research into the molecular bases of malignant diseases has yielded development many novel agents with potential antitumor activity. Evidence for a causative role epidermal growth factor receptor (EGFR), which is now regarded as an excellent target cancer chemotherapy in human cancer, leads to EGFR inhibitors. Two classes anti-EGFR are currently clinical use: monoclonal antibodies directed at extracellular domain receptor, and low-molecular-weight tyrosine kinase inhibitors acting...
Background: First-line decision making is the key to successful care of mCRC patients and RAS/BRAF status crucial select best targeted agent. In hub centers, a relevant proportion referred from small volume centers may not have standard tissue-based (STB) molecular results available at time first visit (T0). Liquid biopsy (LB) help circumvent these hurdles. Methods: A monoinstitutional prospective head-to-head comparison LB versus (vs.) STB testing was performed in real-world setting....
Summary Objective The current standard of treatment Buruli ulcer disease (BUD) is surgical excision lesions. Excision size determined macroscopically assuming the complete removal all infected tissue. However, dissemination infection beyond margins into apparently healthy tissue, possibly associated with recurrences, cannot be excluded in this way. To assess central to peripheral progression Mycobacterium ulcerans and mycobacterial infiltration margins, excised tissue was examined for signs...
Research into the molecular bases of malignant diseases has yielded development many novel agents with potential antitumor activity. Evidence for a causative role epidermal growth factor receptor (EGFR), which is now regarded as an excellent target cancer chemotherapy in human cancer, leads to EGFR inhibitors. Two classes anti-EGFR are currently clinical use: monoclonal antibodies directed at extracellular domain receptor, and low-molecular-weight tyrosine kinase inhibitors acting...
Aim: High levels of TS have been associated with a worse clinical outcome in several cancers including epithelial ovarian cancer (EOC). The gene (TYMS) is highly polymorphic and has an effect on mRNA/protein expression. Materials & methods: Six TYMS polymorphisms were investigated for overall survival (OS) 216 EOC patients: 1494ins/del, TSER (variable number tandem repeats 28 bp), G>C, 1053C>T, IVS6-68C>T 1122A>G. Results: In multivariate analysis, 1494 del/del genotype was significant...